Acrivon Therapeutics (ACRV)

The company’s lead clinical asset is ACR-368, also known as prexasertib, a targeted oncology candidate being developed for cancers where disruption of DNA damage response and cell-cycle regulation may create therapeutic vulnerability. These pathways are central to how cancer cells repair damage and continue dividing, and they are a major area of research across oncology drug development.

Acrivon’s pipeline also includes programs directed at important regulatory nodes in the DNA damage response and cell-cycle network. These include work around WEE1 and PKMYT1, both protein kinases involved in controlling cell-cycle progression. ACR-2316 is a selective dual WEE1/PKMYT1 inhibitor, while ACR-6840 is a development candidate targeting CDK11, another cell-cycle-related target with potential relevance in cancer.

Acrivon operates as a research and development-focused company, with its business centered on advancing oncology candidates through preclinical and clinical studies. Its distinguishing feature is the integration of drug development with a responder-identification platform intended to enrich clinical trials for patients most likely to benefit. This model reflects a broader shift in cancer treatment toward biomarker-guided medicines and more selective clinical development strategies.